Chief Executive Officer
Mr. Greenman was most recently Vice President and Interim CEO for HealthCare IT, Inc. (HCIT) – a biomedical software and services firm specializing in human tissue banking.
While at HCIT, he formed partnerships with global pharmaceutical companies as well as major academic medical institutions to standardize the management of donated human specimens by using advanced logistics and clinical data management software and protocols.
Prior to HCIT, Mr. Greenman led the strategic marketing function for Philips Medical System's Remote Patient Management Division, part of Philip's New Ventures organization. In this role, Mr. Greenman was responsible for commercialization and partnership strategy for a cardiovascular disease management platform technology.
Prior to Philips, Mr. Greenman was Director of Business Development for Ardais Corporation, a biorepository management company that set the standard in tissue banking bioethics, logistics, and quality by building one of the largest repositories of research quality commercially available cancer tissue in the world.
Mr. Greenman was the founder of medXtend Corporation, a venture backed healthcare services company providing medical devices and services for use by Radiologists and Primary Care Physicians. Additionally, Mr. Greenman worked in a variety of healthcare consulting roles within Accenture's Healthcare Practice, KPMG Peat Marwick's Healthcare Strategy Group, Oracle, and the Boston Consulting Group.
Mr. Greenman holds an M.B.A. from the Wharton School of Business in Healthcare Management.
Dr. Peter Verlander
Chief Scientific Officer
Dr. Verlander was most recently the Associate Director for Strategic Development of the Laboratory for Molecular Medicine (LMM) within the Harvard Medical School - Partners Healthcare Center for Genetics and Genomics, where he helped transform the vision of personalized medicine into reality by translating research discoveries into breakthrough molecular diagnostic tests.
Dr. Verlander led the team that developed the first clinical test for detection of EGFR mutations predicting therapeutic response in lung adenocarcinoma. Dr. Verlander is a molecular geneticist with nearly 15 years of experience in various aspects of human genetics in both academia and industry, including research at The Rockefeller University in New York on the molecular genetics of Fanconi anemia (FA), a DNA breakage disorder leading to bone marrow failure and increased risk of leukemia.
In 2000, Dr. Verlander came to Boston to join Millennium Predictive Medicine’s Patient Management effort before joining the LMM in 2003.
Dr. Verlander received his PhD in Microbiology from Duke University.
Vice President, Global Marketing and Sales
Bruce brings to the Store-a-Tooth family over two decades of service in healthcare, supporting both medical and dental professionals and their patients in the fields of dentistry and eye care.
At Optiva Corporation, designers of the Sonicare electric toothbrush, Bruce played an important role in educating dentists and patients globally about the importance of preventive dentistry and the role that good brushing habits and professional dental care play in ensuring healthy teeth and gums.
At Bausch & Lomb Inc, the global eye care company, he supported the launch of innovative new products, and helped to bring Bausch & Lomb products and services to eye care professionals and consumers in Europe, the Middle East and Africa.
Bruce lived and worked in Europe for nearly a decade, and has traveled in support of healthcare professionals and patients in over 40 countries worldwide.
Dr. Joseph Laning, PhD
Vice President, Technology
Dr. Joseph Laning is an experienced executive, manager and scientist with over 16 years' experience in the fields of wound care, regenerative medicine, and cell therapy.
He began his career at Organogenesis, Inc. where he developed and implemented pre-clinical investigations and subsequently managed all patient immunology safety testing leading to the PMA approval of Apligraf™.
In 2002, he joined ViaCell, Inc. where he served as Director of Therapeutic Development and subsequently Senior Director of Analytical Biology. In these roles he oversaw strategic and operational scientific plans leading to successful approval of both IND and IDE FDA filings and completion of the company’s cell therapy clinical trial.
As part of these efforts Dr. Laning managed numerous scientific joint ventures with Amgen, J&J, and Alnylam investigating combinatorial stem cell product development initiatives in cardiac repair and hematopoietic reconstitution. He subsequently brought his extensive experience in scientific management and product development to scientific and business consulting opportunities in industry and academics as Founder and Principal of JCLaning Bio-Consulting.
Most recently he joined the Massachusetts Human Stem Cell Bank and Registry as Executive Director eager to complete the important tasks required to develop the Bank & Registry into the world class resource envisioned at its inception. He received his BA in Biology from Boston University and his PhD in Immunology from Harvard University.